RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Giving letrozole before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well neoadjuvant letrozole works in treating postmenopausal women who are undergoing surgery for estrogen-receptor positive or progesterone-receptor positive stage II, stage IIIA, or stage IIIB breast cancer.

Condition	Treatment or Intervention	Phase
stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer	Drug: letrozole  Procedure: aromatase inhibition  Procedure: conventional surgery  Procedure: endocrine therapy  Procedure: hormone therapy  Procedure: neoadjuvant therapy  Procedure: surgery	Phase II

Further Study Details: 

OBJECTIVES: Primary

• Develop a predictive model of response (based on gene expression profiling) in postmenopausal women with estrogen- and/or progesterone-receptor positive stage II, IIIA, or IIIB breast cancer treated with neoadjuvant letrozole.

Secondary

• Determine the response rate in patients treated with this drug.
• Determine changes in Ki67 proliferation rates in patients treated with this drug.
• Determine the rate of improvement in surgical outcomes in patients treated with this drug.
• Determine the long-term outcomes in patients treated with this drug.
• Determine the safety of this drug in these patients.
• Determine mechanisms of resistance to this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive neoadjuvant oral letrozole once daily for 16 weeks in the absence of disease progression. Patients then undergo breast surgery one day after the last dose of letrozole. Patients with partial response after 16 weeks may continue to receive letrozole for an additional 8 weeks before undergoing breast surgery.

Patients are followed within 4 weeks after definitive surgery and then annually for 10 years.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.

Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed infiltrating adenocarcinoma of the breast by core needle biopsy
• Clinical stage T2-T4a-c, N0-2, M0
• Palpable and measurable disease
• Previously untreated disease
• Benefits from neoadjuvant therapy that would improve surgical outcome AND meets criteria for 1 of the following:
• Marginal candidate for lumpectomy (e.g., lumpectomy feasible but patient at risk for positive margins or poor cosmetic outcome) AND patient desires breast-conserving surgery
• Ineligible for lumpectomy due to size of primary tumor, but modified radical mastectomy feasible AND patient desires breast-conserving surgery
• Inoperable disease AND systemic therapy required for disease to become operable by modified radical mastectomy
• Bilateral primary tumors allowed provided both tumors are consistent with entry criteria
• No inflammatory carcinoma (defined as peau d' orange affecting at least one third of the breast)
• Direct extension of the tumor to the skin allowed
• No metastatic breast disease, except isolated ipsilateral supraclavicular lymphadenopathy
• Hormone receptor status:
• Estrogen- and/or progesterone-receptor positive disease based on 10% or more nuclear staining of the invasive component of the tumor

PATIENT CHARACTERISTICS: Age

• Postmenopausal

Sex

• Female

Menopausal status

• Postmenopausal, defined as meeting 1 of the following criteria:
• Cessation of menstrual periods for at least 1 year
• Bilateral surgical oophorectomy
• Follicle-stimulating hormone and estradiol levels in the postmenopausal range

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• No severe liver dysfunction that would preclude study participation

Renal

• Not specified

Other

• Willing and able to provide biopsy material
• Willing to undergo breast surgery after neoadjuvant treatment
• No condition (e.g., confusion, infirmity, or alcoholism) that would preclude study compliance
• No other concurrent active and progressive invasive malignancies
• No other concurrent severe disease that would preclude study participation

PRIOR CONCURRENT THERAPY: Biologic therapy

• No concurrent immunotherapy or biological response modifiers for breast cancer

Chemotherapy

• No prior chemotherapy for breast cancer
• No concurrent chemotherapy for breast cancer

Endocrine therapy

• At least 2 weeks since prior hormone replacement therapy or phytoestrogenic herbal, alternative, or over-the-counter (OTC) sex hormone remedies
• No prior hormonal agents for breast cancer
• No prior aromatase inhibitors, tamoxifen, raloxifene, or other antiestrogen or selective estrogen receptor modulators
• No concurrent drugs known to affect sex hormone status, including hormone replacement therapy or phytoestrogenic herbal, alternative, or OTC remedies
• No other concurrent endocrine therapy for breast cancer

Radiotherapy

• No prior radiotherapy for breast cancer
• No concurrent radiotherapy for breast cancer

Surgery

• Prior sentinel node biopsy allowed
• No other concurrent surgery for breast cancer

Other

• More than 30 days since prior non-approved or experimental drugs
• Concurrent bisphosphonates for osteoporosis allowed
• No other concurrent treatment for breast cancer

Missouri
      Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis,  Missouri,  63110,  United States; Recruiting

Study chairs or principal investigators

Matthew J. Ellis, MD, PhD, RRCP,  Principal Investigator,  Barnes-Jewish Hospital   

Study ID Numbers:  CDR0000361963; WU-03-0586; NCT00084396
Record last reviewed:  May 2004
Last Updated:  April 5, 2005
Record first received:  June 10, 2004
ClinicalTrials.gov Identifier:  NCT00084396
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08